Live attenuated vaccines alone or in combination with an adenovirus-based vaccine protect mice lacking IFN-γ against pneumonic plague
Emily K. Hendrix, Jian Sha, Paul B. Kilgore, Blake H. Neil, Atul K. Verma, Heidi Spratt, Ashok K. Ch / science - Science Translational Medicine, Volume 18, Issue 859, July 2026.
AI Summary: Preclinical work shows that a live attenuated vaccine, alone or combined with an adenovirus vector, protected mice lacking key interferon‑gamma defenses from pneumonic plague. The strategy delivered surprising protection in immunocompromised models, suggesting a potential path forward for vaccines designed to work even when classical immune pathways are impaired.
Related Stories
Dual Lassa–rabies vaccine phase 1 shows safety in humans / 2 months
Moderna launches mRNA bird‑flu vaccine trial as preparedness ramps up / 4 months
DR Congo Ebola outbreak tops 3,000; Bundibugyo vaccine trial begins / 6 wks
Pfizer's Lyme vaccine heads to FDA after mixed trial results / 5 months
Triple‑dose early treatment clears HIV in newborn primates study / 24 days
UK begins human testing of first AI-designed 'universal' vaccine / 3 months
Favipiravir shows promise in Lassa fever Phase 2 trial / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Telemedicine, Vaccine Safety, Animal Health, Medicare Advantage (not listed) and look for the RSS link.
StackHealth Time Machine